Adaptimmune Therapeutics plc (473A) — Net Asset Quality Index
Adaptimmune Therapeutics plc (473A) has a Net Asset Quality Index of -54.3% as of June 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €130.63 Million minus total liabilities of €201.59 Million yields net assets of €-70.96 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read debt load of Adaptimmune Therapeutics plc for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Adaptimmune Therapeutics plc Net Asset Quality Index Over Time (2016–2024)
This chart shows how Adaptimmune Therapeutics plc's Net Asset Quality Index has evolved across 9 annual periods from 2016 to 2024. As of June 2025, the index stands at -54.3%, representing net assets of €-70.96 Million against total assets of €130.63 Million EUR. For live market cap and overall valuation, see 473A market cap overview.
Annual Net Asset Quality Index for Adaptimmune Therapeutics plc (2016–2024)
The table below presents the year-by-year Net Asset Quality Index for Adaptimmune Therapeutics plc from 2016 to 2024, covering 9 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check Adaptimmune Therapeutics plc (473A) strategic asset index to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 4.8% | €11.85 Million | €245.96 Million | €234.11 Million | ▼ -9.2 pp |
| 2023 | 14.0% | €39.51 Million | €282.62 Million | €243.10 Million | ▼ -10.9 pp |
| 2022 | 24.9% | €81.88 Million | €328.92 Million | €247.04 Million | ▼ -19.0 pp |
| 2021 | 43.9% | €205.96 Million | €469.55 Million | €263.58 Million | ▼ -31.8 pp |
| 2020 | 75.6% | €341.23 Million | €451.14 Million | €109.92 Million | ▲ +7.5 pp |
| 2019 | 68.1% | €123.64 Million | €181.54 Million | €57.91 Million | ▼ -21.1 pp |
| 2018 | 89.2% | €246.88 Million | €276.74 Million | €29.85 Million | ▲ +17.0 pp |
| 2017 | 72.2% | €202.98 Million | €281.15 Million | €78.16 Million | ▲ +1.4 pp |
| 2016 | 70.8% | €166.14 Million | €234.51 Million | €68.37 Million | — |